Saturday, 24 Oct 2026

Empowering Chinese Pharma’s Global Expansion

Contact US
Insight,  China's Pharmaceutical Industry
  • Home
  • About US
  • Policy Hub
  • Categories
    • Drug
    • Company
    • Deals
    • Policy / Regulatory
    • Medical Device
    • R&D
    • Legal / IP
    • Digital
  • Privacy Policy
  • Contact US
My News
  • Cancer
  • Clinical trial approval / initiation
  • Product approvals
  • Clinical trial results
  • Finance
  • ADC / XDC
  • Finanical Reports
  • Biotech
  • Market approval filings
  • PD-1/L1
Insight,  China's Pharmaceutical IndustryInsight,  China's Pharmaceutical Industry
  • Read History
Search
  • Pages
    • Home
    • Blog Index
    • POLICY HUB
    • Contact Us
  • Personalized
    • Read History
  • Categories
    • Company
    • Drug
    • Policy / Regulatory
    • Medical Device
    • R&D
    • Digital
    • Legal / IP
    • Deals
Have an existing account? Sign In
Follow US
Haisco Pharmaceutical’s HSK47388 Gears Up for New Autoimmune Trial – NMPA Approval
CompanyDrug

Haisco Pharmaceutical’s HSK47388 Gears Up for New Autoimmune Trial – NMPA Approval

September 4, 2025
Boji Medical’s FCZR Approved for Otomycosis Trials – First Liquid Eardrop in China
CompanyDrug

Boji Medical’s FCZR Approved for Otomycosis Trials – First Liquid Eardrop in China

September 4, 2025
Hengrui’s HRS9531 Injection Clears NMPA Approval, Hits 19.2% Weight Loss in Phase 3
CompanyDrug

Hengrui’s HRS9531 Injection Clears NMPA Approval, Hits 19.2% Weight Loss in Phase 3

September 4, 2025
Biocytogen, Merck Partner on Antibody‑Conjugated Lipid Nanoparticles
CompanyDeals

Biocytogen, Merck Partner on Antibody‑Conjugated Lipid Nanoparticles

September 4, 2025
Argo Biopharma, Novartis Expand siRNA Collaboration for Cardiovascular Drugs
CompanyDeals

Argo Biopharma, Novartis Expand siRNA Collaboration for Cardiovascular Drugs

September 4, 2025
ChemPartner & Toposcend Form $200 M Healthcare Fund to Back Innovative Drugs
CompanyDeals

ChemPartner & Toposcend Form $200 M Healthcare Fund to Back Innovative Drugs

September 4, 2025
AbbVie Secures NMPA Priority Review for Epcoritamab in Relapsed Follicular Lymphoma
CompanyDrug

AbbVie Secures NMPA Priority Review for Epcoritamab in Relapsed Follicular Lymphoma

September 4, 2025
Replicate Bioscience Teams With Novo Nordisk On srRNA‑Powered Metabolic Drugs
CompanyDeals

Replicate Bioscience Teams With Novo Nordisk On srRNA‑Powered Metabolic Drugs

September 4, 2025
Simcere Secures NMPA Approval for Deunoxavir Marboxil, First Pediatric Influenza Drug
CompanyDrug

Simcere Secures NMPA Approval for Deunoxavir Marboxil, First Pediatric Influenza Drug

September 4, 2025
FDA Unveils RDEP to Accelerate Rare Disease Therapy Development
Policy / Regulatory

FDA Unveils RDEP to Accelerate Rare Disease Therapy Development

September 4, 2025
Aosaikang Launches Phase III Trial of ASK202 with Leatinib for NSCLC
CompanyDrug

Aosaikang Launches Phase III Trial of ASK202 with Leatinib for NSCLC

September 4, 2025
Ab&B Bio‑Tech Wins NMPA Approval for First‑Ever Quadrivalent Influenza Subunit Vaccine
CompanyDrug

Ab&B Bio‑Tech Wins NMPA Approval for First‑Ever Quadrivalent Influenza Subunit Vaccine

September 4, 2025
1 2 … 72 73 74 75 76 … 289 290
Insight,  China's Pharmaceutical Industry

Information You Can Trust: Stay instantly connected with breaking stories and live updates. From politics and technology to entertainment and beyond, we provide real-time coverage you can rely on, making us your dependable source for 24/7 news.

Youtube Medium Rss

About Company

  • Contact Us
  • Advertise with US
  • Complaint
  • Our Team
  • Our Values
  • Privacy Policy
Subscribe Now for Real-time Updates on the Latest Stories!

© 2026 Fineline Information & Technology. Independent intelligence on China’s pharmaceutical industry.  All Rights Reserved.

Fineline Information & Technology
Welcome to Fineline Cube!
Username or Email Address
Password

Lost your password?

Not a member? Sign Up